ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,508Medicare Part D Prescriptions Filled, Including Refills

Rank: 67 out of 617

$423K Total Retail Price of All Prescriptions

Rank: 140 out of 617

414 Patients Receiving at Least One Drug in Part D
82%Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 414 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

14% of this provider’s 414 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

1% of this provider’s 10,253 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 790 711 1 1
WARFARIN SODIUM 482 447 2 7
OMEPRAZOLE 441 383 3 3
FUROSEMIDE 394 381 4 4
SIMVASTATIN 376 347 5 2
AMLODIPINE BESYLATE 363 324 6 6
SERTRALINE HCL 300 265 7 20
METOPROLOL SUCCINATE 270 270 8 12
HYDROCHLOROTHIAZIDE 245 225 9 13
METOPROLOL TARTRATE 230 207 10 11
POTASSIUM CHLORIDE 217 207 11 10
LISINOPRIL 214 197 12 5
HYDROCODONE-ACETAMINOPHEN 210 154 S3 13 8
METFORMIN HCL 182 170 14 9
GABAPENTIN 156 132 15 16
PRAVASTATIN SODIUM 154 154 16 21
ALENDRONATE SODIUM 149 149 17 25
ZOLPIDEM TARTRATE 145 113 18 23
LANTUS 144 127 19 39
POLYETHYLENE GLYCOL 3350 139 131 20 32
ATORVASTATIN CALCIUM 138 113 21 14
LOSARTAN POTASSIUM 117 105 22 22
FAMOTIDINE 111 102 23 54
ISOSORBIDE MONONITRATE ER 109 109 24 52
ENALAPRIL MALEATE 107 107 25 34
AMIODARONE HCL 101 89 26 129
PREDNISONE 100 98 27 31
SPIRONOLACTONE 95 95 28 42
TRAMADOL HCL 92 89 29 15
CITALOPRAM HBR 92 81 29 18
ATENOLOL 80 67 31 17
CARVEDILOL 80 78 31 19
FLUTICASONE PROPIONATE 76 63 33 36
KLOR-CON M20 75 48 34 116
CYMBALTA 75 70 34 49
FENTANYL 71 61 S2 36 45
DONEPEZIL HCL 68 68 37 30
NAMENDA 65 65 38 35
KLOR-CON 10 64 64 39 126
PROPAFENONE HCL 63 63 40 278
AZITHROMYCIN 61 51 41 70
GLIPIZIDE ER 61 49 41 94
ALLOPURINOL 59 59 43 27
RANITIDINE HCL 56 52 44 40
CIPROFLOXACIN HCL 56 55 44 60
TAMSULOSIN HCL 56 56 44 26
DIOVAN 55 55 47 41
CRESTOR 54 51 48 28
DIOVAN HCT 53 53 49 97
SULFAMETHOXAZOLE-TRIMETHOPRIM 53 48 49 91
LISINOPRIL-HYDROCHLOROTHIAZIDE 50 49 51 29
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 4, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.